Literature DB >> 3143768

Failure of ketoconazole to cure chronic murine Chagas' disease.

R McCabe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3143768     DOI： 10.1093/infdis/158.6.1408

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  7 in total

1.  A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

Authors:  Patricia S Doyle; Chiung-Kuang Chen; Jonathan B Johnston; Stephanie D Hopkins; Siegfried S F Leung; Matthew P Jacobson; Juan C Engel; James H McKerrow; Larissa M Podust
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi.

Authors:  J A Urbina; R Lira; G Visbal; J Bartrolí
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.

Authors:  J Molina; O Martins-Filho; Z Brener; A J Romanha; D Loebenberg; J A Urbina
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

4.  Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice.

Authors:  R McCabe; S Meagher; B Mullins
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

5.  Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.

Authors:  J A Urbina; G Payares; L M Contreras; A Liendo; C Sanoja; J Molina; M Piras; R Piras; N Perez; P Wincker; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

6.  Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell death.

Authors:  Rafael Luis Kessler; Maurilio José Soares; Christian Macagnan Probst; Marco Aurélio Krieger
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

7.  4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.

Authors:  Claudia M Calvet; Debora F Vieira; Jun Yong Choi; Danielle Kellar; Michael D Cameron; Jair Lage Siqueira-Neto; Jiri Gut; Jonathan B Johnston; Li Lin; Susan Khan; James H McKerrow; William R Roush; Larissa M Podust
Journal:  J Med Chem       Date:  2014-08-19       Impact factor: 7.446
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.